Physician

Cara C Bondly, M.D.

According to 2025 Medicare claims, Cara Bondly, M.D. (NPI: 1588637250) practices hematology/oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35205-1202.

Bondly's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 4,735 traditional Medicare patients, billed 219,476 HCPCS/CPT codes, and received $3,960,473 in Medicare payments. The top billing code was 82746 (Folic acid level, serum). Part D data shows 5,169 prescription claims across 590 beneficiaries totaling $7,783,796 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 19 claims. Open Payments data shows 139 records totaling $3,191. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,679,591 and ending at $3,960,473. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,222,156 to $7,783,796. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	611	231,867	$2,679,591
2016	661	263,831	$3,006,558
2017	621	254,072	$2,709,885
2018	3,584	296,695	$3,162,323
2019	4,927	364,206	$4,422,248
2020	4,679	263,438	$3,616,056
2021	4,707	278,970	$3,045,862
2022	4,757	295,494	$3,468,386
2023	4,708	194,668	$2,552,224
2024	4,735	219,476	$3,960,473

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	297	2,785	$1,222,156
2016	355	3,157	$1,706,695
2017	400	3,313	$2,293,337
2018	402	3,276	$2,483,095
2019	403	3,160	$2,385,095
2020	429	3,558	$2,383,151
2021	506	4,503	$2,862,504
2022	561	4,934	$4,243,719
2023	597	5,016	$5,780,824
2024	590	5,169	$7,783,796

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	24	246	$38,834
2016	N/R	141	$18,840
2017	N/R	12	$1,220
2018	11	46	$6,903
2019	13	28	$5,013
2020	32	109	$14,703
2021	32	78	$10,731
2022	16	69	$3,782
2023	16	31	$2,411
2024	12	19	$2,142

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82746	Folic acid level, serum	1,557	2,480	$14
82728	Ferritin (blood protein) level	2,808	6,286	$13
80053	Blood test, comprehensive group of blood chemicals	4,486	16,024	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,613	6,094	$8
83540	Iron level	2,332	5,003	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	63	2,010	$1,049,001
Lenalidomide	Lenalidomide	68	1,897	$899,706
Venclexta	Venetoclax	47	1,410	$837,167
Pomalyst	Pomalidomide	39	987	$776,869
Ibrance	Palbociclib	44	1,232	$681,305

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	12	19	$2,142

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$3,191	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Cara C. Bondly, M.D.?

Tedicare shows public-source Medicare data for Cara C. Bondly, M.D. (NPI 1588637250), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Cara C. Bondly, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Cara C. Bondly, M.D.?

Cara C. Bondly, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Cara C. Bondly, M.D. have Open Payments data?

Cara C. Bondly, M.D. has 139 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.